Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial

Phase 2 Terminated 8 enrolled Canadian Critical Care Trials Group Canadian Institutes of Health Research (CIHR) · collab Public Health Agency of Canada (PHAC) · collab The Physicians' Services Incorporated Foundation · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.

Timeline

Start: 2009-12
Primary completion: 2010-05
Completion: 2010-08

Outcome

Outcome not reported

Stopped: “H1N1 pandemic concluded”

Publications

Background Burns KE, Chant C, Smith O, Cuthbertson B, Fowler R, Cook DJ, Kruger P, Webb S, Alhashemi J, Dominguez-Cherit G, Zala C, Rubenfeld GD, Marshall JC. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. Trials. 2011 Mar 9;12:70. doi: 10.1186/1745-6215-12-70.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	20 mg	Other